loading
Rapt Therapeutics Inc stock is traded at $1.105, with a volume of 1.04M. It is up +0.45% in the last 24 hours and down -37.99% over the past month. RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$1.105
Open:
$1.19
24h Volume:
1.04M
Relative Volume:
2.20
Market Cap:
$37.41M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-0.4108
EPS:
-2.69
Net Cash Flow:
$-98.17M
1W Performance:
-36.57%
1M Performance:
-37.99%
6M Performance:
-72.52%
1Y Performance:
-92.15%
1-Day Range:
Value
$1.01
$1.22
1-Week Range:
Value
$1.01
$1.955
52-Week Range:
Value
$1.01
$27.35

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
Name
Rapt Therapeutics Inc
Name
Phone
(650) 489-9000
Name
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
Employee
70
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
RAPT's Discussions on Twitter

Compare RAPT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
RAPT 1.10 37.41M 3.25M -116.80M -98.17M -2.69
VRTX 467.34 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.42 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.61 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.62 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.69 24.08B 3.30B -501.07M 1.03B 11.54

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-24 Downgrade Wolfe Research Outperform → Peer Perform
May-10-24 Downgrade Barclays Overweight → Equal Weight
May-10-24 Downgrade Guggenheim Buy → Neutral
Feb-22-24 Downgrade UBS Buy → Neutral
Feb-21-24 Downgrade H.C. Wainwright Buy → Neutral
Feb-21-24 Downgrade JP Morgan Overweight → Neutral
Feb-21-24 Downgrade Leerink Partners Outperform → Market Perform
Feb-20-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-16-24 Initiated Evercore ISI Outperform
Feb-15-24 Initiated Wolfe Research Outperform
Sep-14-23 Initiated Berenberg Buy
Aug-09-23 Initiated Stifel Buy
Jun-15-23 Initiated Barclays Overweight
Jan-04-23 Initiated Guggenheim Buy
Dec-01-22 Initiated Goldman Buy
Sep-21-22 Initiated CapitalOne Overweight
May-24-22 Resumed Cantor Fitzgerald Overweight
Dec-09-21 Initiated JP Morgan Overweight
Aug-12-21 Initiated SVB Leerink Outperform
Jun-21-21 Initiated Piper Sandler Overweight
Jun-01-20 Initiated H.C. Wainwright Buy
May-19-20 Initiated Cantor Fitzgerald Overweight
Apr-13-20 Initiated ROTH Capital Buy
Nov-25-19 Initiated BMO Capital Markets Outperform
Nov-25-19 Initiated UBS Buy
Nov-25-19 Initiated Wells Fargo Outperform
View All

Rapt Therapeutics Inc Stock (RAPT) Latest News

pulisher
Nov 17, 2024

RAPT Therapeutics announces option repricing to retain talent By Investing.com - Investing.com Nigeria

Nov 17, 2024
pulisher
Nov 15, 2024

Leerink Partnrs Issues Optimistic Forecast for RAPT Earnings - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Leerink Partnrs Expects Lower Earnings for RAPT Therapeutics - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

RAPT Therapeutics' SWOT analysis: biotech firm faces challenges, seeks new path - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

RAPT Therapeutics Reports Improved Q3 2024 Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

RAPT Therapeutics' (RAPT) Hold Rating Reaffirmed at Stifel Nicolaus - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Wells Fargo & Company Has Lowered Expectations for RAPT Therapeutics (NASDAQ:RAPT) Stock Price - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

RAPT Therapeutics (NASDAQ:RAPT) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

RAPT Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

RAPT Therapeutics Narrows Q3 Loss by 41%, Cuts R&D Spend Amid Restructuring | RAPT Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

RAPT Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Australia

Nov 12, 2024
pulisher
Nov 12, 2024

RAPT Therapeutics Inc (RAPT) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

RAPT Therapeutics stock hits 52-week low at $1.49 - Investing.com

Nov 12, 2024
pulisher
Nov 11, 2024

Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4 - Citeline News & Insights

Nov 11, 2024
pulisher
Nov 11, 2024

Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Nasdaq Moves Lower; Canaan Shares Surge - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

JPMorgan cuts Rapt Therapeutics to Underweight By Investing.com - Investing.com UK

Nov 11, 2024
pulisher
Nov 11, 2024

JPMorgan Chase & Co. Downgrades RAPT Therapeutics (NASDAQ:RAPT) to Underweight - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn

Nov 11, 2024
pulisher
Nov 11, 2024

RAPT scraps zelnecirnon program, stock plunges 46% (update) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 11, 2024

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - Clinical Trials Arena

Nov 11, 2024
pulisher
Nov 11, 2024

Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn

Nov 11, 2024
pulisher
Nov 11, 2024

Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Rapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines Trials - MarketWatch

Nov 11, 2024
pulisher
Nov 11, 2024

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Based on Recent FDA Feedback RAPT Therapeutics Stops - GlobeNewswire

Nov 11, 2024
pulisher
Nov 11, 2024

RAPT Therapeutics Halts Key Drug Program After FDA Safety Concerns, Liver Injury | RAPT Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Contrasting RAPT Therapeutics (NASDAQ:RAPT) and Elanco Animal Health (NYSE:ELAN) - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth? - Simply Wall St

Nov 10, 2024
pulisher
Nov 09, 2024

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky - Yahoo Finance

Nov 09, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN

Nov 04, 2024
pulisher
Oct 22, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 21, 2024

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com

Oct 21, 2024
pulisher
Oct 10, 2024

RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com

Oct 10, 2024
pulisher
Oct 04, 2024

Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

RAPT Therapeutics Inc (RAPT) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

Cubist Systematic Strategies LLC Increases Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

XTX Topco Ltd Invests $108,000 in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

Oct 02, 2024
pulisher
Sep 30, 2024

RAPT Therapeutics' SWOT analysis: biotech stock faces clinical hurdles - Investing.com

Sep 30, 2024
pulisher
Sep 29, 2024

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now - Yahoo Finance

Sep 29, 2024
pulisher
Sep 26, 2024

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability - Insider Monkey

Sep 25, 2024
pulisher
Sep 24, 2024

15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers - Insider Monkey

Sep 24, 2024
pulisher
Sep 23, 2024

RAPT stock touches 52-week low at $1.76 amid sharp annual decline - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

Daily Progress: RAPT Therapeutics Inc (RAPT) Drop -7.25, Closing at 1.79 - The Dwinnex

Sep 23, 2024
pulisher
Sep 20, 2024

Federated Hermes Inc. Boosts Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat

Sep 20, 2024
pulisher
Sep 16, 2024

Acadian Asset Management LLC Raises Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat

Sep 16, 2024
pulisher
Sep 10, 2024

RAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $2.00 by Analysts at UBS Group - Defense World

Sep 10, 2024

Rapt Therapeutics Inc Stock (RAPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Rapt Therapeutics Inc Stock (RAPT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Brockstedt Dirk G.
Chief Scientific Officer
Dec 29 '23
Option Exercise
6.18
8,000
49,440
27,070
HO WILLIAM
Chief Medical Officer
Dec 21 '23
Sale
21.68
2,500
54,200
15,020
HO WILLIAM
Chief Medical Officer
Nov 28 '23
Sale
13.72
1,500
20,580
17,520
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):